OSI-461

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameOSI-461
Drug Alias NameCP-461OSI-461CEL-031
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 2A inhibitorsPhosphodiesterase 5A inhibitors
TargetsPhosphodiesterase 2APhosphodiesterase 5A
Therapy Area/IndicationsCrohn DiseaseProstatic NeoplasmsCarcinoma, Renal Cell +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstellas Pharma Inc
Active IndicationsN/A
Inactive IndicationsCrohn DiseaseProstatic NeoplasmsCarcinoma, Renal Cell +[5

Other Information

ATC CodeN/A
Related LinksDrugBank